1. Home
  2. STELLA PHARMA NEWS
  3. SPM-011
STELLA PHARMA NEWS
SPM-011
Press Release BNCT SPM-011
July 28th, 2025

Achievement of Primary Endpoints in Phase II Clinical Trial Targeting Angiosarcoma in Japan  —Detailed Trial Results to Be Presented at ESMO Congress 2025—

 We are pleased to announce that the Phase II clinical trial for angiosarc……

READ MORE

Press Release BNCT SPM-011
December 10th, 2024

Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma

We are pleased to announce the completion of the 90-day observation period for ……

READ MORE

Press Release BNCT SPM-011
September 25th, 2024

Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma

Our product Borofalan (10B) (development code: SPM-011), which we are developin……

READ MORE

Press Release BNCT SPM-011
September 10th, 2024

Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma

Stella Pharma completed the enrollment of patients for the domestic phase II do……

READ MORE

Press Release SPM-011 Information
August 30th, 2024

Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma

Stella Pharma announces that it has applied to the Japanese Ministry of Health,……

READ MORE

BNCT SPM-011 Information
December 25th, 2023

Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma

Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……

READ MORE